<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Will</title>
	<atom:link href="http://www.tapanray.in/tag/will/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>e-Patients: Quality and Cost Empowered Patients Will Help Reducing Healthcare Costs in India Significantly</title>
		<link>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly</link>
		<comments>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/#comments</comments>
		<pubDate>Mon, 30 Jul 2012 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Empowered]]></category>
		<category><![CDATA[ePatients]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[help]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India Significantly]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reducing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=59</guid>
		<description><![CDATA[Currently many important stakeholders of the healthcare industry, reportedly, are using or rather exploiting the individual patients not just to derive petty commercials gains, but also for quite significant strategic commercial advantages, mainly due to ignorance or helplessness of a &#8230; <a href="http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/e-patients-quality-and-cost-empowered-patients-will-help-reducing-healthcare-costs-in-india-significantly/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>From Cross-Licensing to ‘Patent Pools’ and&#8230; India: Will there be a ground swell?</title>
		<link>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell</link>
		<comments>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/#comments</comments>
		<pubDate>Mon, 23 May 2011 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Cross]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pools]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[swell]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Will]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=254</guid>
		<description><![CDATA[Since many years, the global pharmaceutical industry has been making effective commercial use of cross-licensing, however, by and large, the industry still does not seem to be quite in favor of  &#8216;Patent Pools&#8217; for various reasons. The ‘Patent Pool’, as &#8230; <a href="http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/from-cross-licensing-to-patent-pools-and-india-will-there-be-a-ground-swell/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A time to keep our nose to the Grindstone &#8211; Competition Act will take care of M&amp;As, come June 2011</title>
		<link>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011</link>
		<comments>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/#comments</comments>
		<pubDate>Mon, 14 Mar 2011 00:30:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CCI]]></category>
		<category><![CDATA[come]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Greenfield]]></category>
		<category><![CDATA[Grindstone]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[June]]></category>
		<category><![CDATA[keep]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[nose]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[our]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[take]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=290</guid>
		<description><![CDATA[Full control of powers on Mergers and Acquisitions of the Competition Commission of India (CCI) effective June 1, 2011, has now been notified. In this evolving scenario, it is indeed difficult to understand, why is the FDI issue on M&#38;A &#8230; <a href="http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-time-to-keep-our-nose-to-the-grindstone-competition-act-will-take-care-of-mas-come-june-2011/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will Global Pharma Majors be successful in their foray into highly competitive generics pharma business offering no (patent) protection of any kind?</title>
		<link>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind</link>
		<comments>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/#comments</comments>
		<pubDate>Mon, 05 Jul 2010 01:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[foray]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[highly]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[into]]></category>
		<category><![CDATA[kind]]></category>
		<category><![CDATA[majors]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[No]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[offering]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[successful]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[their]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=406</guid>
		<description><![CDATA[As reported by IMS Health, emerging markets will register a growth rate of 14% to 17% by 2014, when the developed markets will be growing by 3% to 6% during the same period. It is forecasted that the global pharmaceutical &#8230; <a href="http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-global-pharma-majors-be-successful-in-their-foray-into-highly-competitive-generics-pharma-business-offering-no-patent-protection-of-any-kind/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To restore patients’ confidence MCI has amended its regulations… to strengthen it further will the government consider an Indian version of ‘Physician Payment Sunshine Act’?</title>
		<link>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act</link>
		<comments>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/#comments</comments>
		<pubDate>Mon, 08 Feb 2010 01:30:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amended]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[consider]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[further]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[restore]]></category>
		<category><![CDATA[strengthen]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[version]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=470</guid>
		<description><![CDATA[In today’s India, blatant commercialization of the noble healthcare services has reached its nadir, as it were, sacrificing the ethics and etiquettes both in medical and pharmaceutical marketing practices at the altar of unlimited greed. As a result of fast &#8230; <a href="http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-restore-patients-confidence-mci-has-amended-its-regulations-to-strengthen-it-further-will-the-government-consider-an-indian-version-of-physician-payment-sunshine-act/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Collaborative commercialization of inexpensive smaller incremental innovation in Chemistry will play an important role in bringing affordable new drugs or new drug delivery systems</title>
		<link>http://www.tapanray.in/collaborative-commercialization-of-inexpensive-smaller-incremental-innovation-in-chemistry-will-play-an-important-role-in-bringing-affordable-new-drugs-or-new-drug-delivery-systems/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=collaborative-commercialization-of-inexpensive-smaller-incremental-innovation-in-chemistry-will-play-an-important-role-in-bringing-affordable-new-drugs-or-new-drug-delivery-systems</link>
		<comments>http://www.tapanray.in/collaborative-commercialization-of-inexpensive-smaller-incremental-innovation-in-chemistry-will-play-an-important-role-in-bringing-affordable-new-drugs-or-new-drug-delivery-systems/#comments</comments>
		<pubDate>Mon, 28 Dec 2009 00:30:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[bringing]]></category>
		<category><![CDATA[Chemistry]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[commercialization]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[important]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inexpensive]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[or]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[play]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=685</guid>
		<description><![CDATA[It started in the 17th century: Alchemy, a medieval chemical science and speculative philosophy aiming to achieve the transmutation of the base metals into gold, searching for a universal cure for disease and indefinitely prolonging life, not considered a science &#8230; <a href="http://www.tapanray.in/collaborative-commercialization-of-inexpensive-smaller-incremental-innovation-in-chemistry-will-play-an-important-role-in-bringing-affordable-new-drugs-or-new-drug-delivery-systems/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/collaborative-commercialization-of-inexpensive-smaller-incremental-innovation-in-chemistry-will-play-an-important-role-in-bringing-affordable-new-drugs-or-new-drug-delivery-systems/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China has recently unfolded the blueprints of its new healthcare reform measures, when will India do so?</title>
		<link>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so</link>
		<comments>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/#comments</comments>
		<pubDate>Mon, 14 Sep 2009 01:30:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[blueprints]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[do]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[has]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hospitals]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[its]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[nurses]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recently]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[so]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[unfolded]]></category>
		<category><![CDATA[when]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=780</guid>
		<description><![CDATA[Early April, 2009, China, a country with 1.3 billion people, unfolded a plan for a new healthcare reform process for the next decade to provide safe, effective, convenient and affordable healthcare services to all its citizens. A budgetary allocation of &#8230; <a href="http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/china-has-recently-unfolded-the-blueprints-of-its-new-healthcare-reform-measures-when-will-india-do-so/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Managing expectations of the emerging markets of the world, proactively, will differentiate winners from the rest, in the Global Pharmaceutical Industry.</title>
		<link>http://www.tapanray.in/managing-expectations-of-the-emerging-markets-of-the-world-proactively-will-differentiate-winners-from-the-rest-in-the-global-pharmaceutical-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=managing-expectations-of-the-emerging-markets-of-the-world-proactively-will-differentiate-winners-from-the-rest-in-the-global-pharmaceutical-industry</link>
		<comments>http://www.tapanray.in/managing-expectations-of-the-emerging-markets-of-the-world-proactively-will-differentiate-winners-from-the-rest-in-the-global-pharmaceutical-industry/#comments</comments>
		<pubDate>Mon, 06 Jul 2009 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[differentiate]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Managing]]></category>
		<category><![CDATA[markets]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[proactively]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Will]]></category>
		<category><![CDATA[winners]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=842</guid>
		<description><![CDATA[Change or Perish:In Mid 2007, PricewaterhouseCoopers (PwC) recommended to the research-based global pharmaceutical companies that for sustainable business performance they should move a part of their expenditure from marketing to research. They also recommended that the drug prices should be &#8230; <a href="http://www.tapanray.in/managing-expectations-of-the-emerging-markets-of-the-world-proactively-will-differentiate-winners-from-the-rest-in-the-global-pharmaceutical-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/managing-expectations-of-the-emerging-markets-of-the-world-proactively-will-differentiate-winners-from-the-rest-in-the-global-pharmaceutical-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ensuring ‘health outcomes’ based drugs prescriptions will be more beneficial for the patients in India than just ‘price control’ of drugs</title>
		<link>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs</link>
		<comments>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/#comments</comments>
		<pubDate>Thu, 18 Jun 2009 01:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[beneficial]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ensuring]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[just]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=857</guid>
		<description><![CDATA[Currently the global pharmaceutical market is undergoing a metamorphosis. The concept of ‘evidence-based medicine’ is gaining ground in the developed markets of the world, making the pharmaceutical companies generate requisite ‘health outcomes’ data using similar or equivalent products. Cost of &#8230; <a href="http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ensuring-health-outcomes-based-drugs-prescriptions-will-be-more-beneficial-for-the-patients-in-india-than-just-price-control-of-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global API manufacturers are poised to penetrate the Indian market in a bigger way – will the API &#8216;marketing warfare&#8217; be even more intense, in future?</title>
		<link>http://www.tapanray.in/global-api-manufacturers-are-poised-to-penetrate-the-indian-market-in-a-bigger-way-will-the-api-marketing-warfare-be-even-more-intense-in-future/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-api-manufacturers-are-poised-to-penetrate-the-indian-market-in-a-bigger-way-will-the-api-marketing-warfare-be-even-more-intense-in-future</link>
		<comments>http://www.tapanray.in/global-api-manufacturers-are-poised-to-penetrate-the-indian-market-in-a-bigger-way-will-the-api-marketing-warfare-be-even-more-intense-in-future/#comments</comments>
		<pubDate>Mon, 25 May 2009 01:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[bigger]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Even]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[intense]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[penetrate]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[poised]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[warfare]]></category>
		<category><![CDATA[way]]></category>
		<category><![CDATA[Will]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=878</guid>
		<description><![CDATA[India currently plays a relatively dominant role in the Global Active Pharmaceutical Ingredient (API) Market with China being ahead of India. While this is the current scenario, many experts in this field contemplates that important players from the regulated markets &#8230; <a href="http://www.tapanray.in/global-api-manufacturers-are-poised-to-penetrate-the-indian-market-in-a-bigger-way-will-the-api-marketing-warfare-be-even-more-intense-in-future/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-api-manufacturers-are-poised-to-penetrate-the-indian-market-in-a-bigger-way-will-the-api-marketing-warfare-be-even-more-intense-in-future/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
